Eleni A Greenwood1, Kristine Yaffe2, Melissa F Wellons3, Marcelle I Cedars1, Heather G Huddleston1. 1. Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, California. 2. Department of Psychiatry, University of California San Francisco, San Francisco, California. 3. Department of Medicine, Vanderbilt University, Nashville, Tennessee.
Abstract
OBJECTIVE: To (i) determine whether women with polycystic ovary syndrome (PCOS) from a population-based cohort experience elevated depression symptoms and (ii) characterize the trajectory of symptoms over the lifespan. DESIGN: The association between PCOS and longitudinal depression scores was investigated among 1127 black and white women participating in Coronary Artery Risk Development in Young Adults study. PCOS was ascertained at baseline (ages 20 to 32) by U.S. National Institutes of Health (NIH) criteria, incorporating androgens and symptoms of oligomenorrhea and hirsutism. The Center for Epidemiologic Studies-Depression (CES-D) scale was repeated prospectively in 5-year intervals over 25 years. Mixed-effects models evaluated the association between depression scores and PCOS after adjustment for confounders and characterized the trajectory of scores. The impact of race was explored. RESULTS: Eighty-three of 1127 (7.4%) participants met NIH PCOS criteria. Of these, 33 (40%) were black and 50 (60%) were white. CES-D scores were higher among women with PCOS [coefficient (coef) 2.51; 95% CI 1.49, 3.54; P < 0.01] across the lifespan. Scores decreased across the lifespan in women with and without PCOS (coef -0.1 point per year; P < 0.001). Black women experienced higher depression burden than white women (coef 1.80; 95% CI 1.20, 2.41; P < 0.001); however, an interaction was not detected between PCOS and race (P = 0.68). CONCLUSIONS: Women with PCOS-NIH from a population-based cohort are at risk for higher depression scores across the lifespan. Depression scores decline over time in women with PCOS in a trajectory similar to that in women without PCOS. Racial differences in depression risk should be acknowledged clinically and further explored.
OBJECTIVE: To (i) determine whether women with polycystic ovary syndrome (PCOS) from a population-based cohort experience elevated depression symptoms and (ii) characterize the trajectory of symptoms over the lifespan. DESIGN: The association between PCOS and longitudinal depression scores was investigated among 1127 black and white women participating in Coronary Artery Risk Development in Young Adults study. PCOS was ascertained at baseline (ages 20 to 32) by U.S. National Institutes of Health (NIH) criteria, incorporating androgens and symptoms of oligomenorrhea and hirsutism. The Center for Epidemiologic Studies-Depression (CES-D) scale was repeated prospectively in 5-year intervals over 25 years. Mixed-effects models evaluated the association between depression scores and PCOS after adjustment for confounders and characterized the trajectory of scores. The impact of race was explored. RESULTS: Eighty-three of 1127 (7.4%) participants met NIH PCOS criteria. Of these, 33 (40%) were black and 50 (60%) were white. CES-D scores were higher among women with PCOS [coefficient (coef) 2.51; 95% CI 1.49, 3.54; P < 0.01] across the lifespan. Scores decreased across the lifespan in women with and without PCOS (coef -0.1 point per year; P < 0.001). Black women experienced higher depression burden than white women (coef 1.80; 95% CI 1.20, 2.41; P < 0.001); however, an interaction was not detected between PCOS and race (P = 0.68). CONCLUSIONS:Women with PCOS-NIH from a population-based cohort are at risk for higher depression scores across the lifespan. Depression scores decline over time in women with PCOS in a trajectory similar to that in women without PCOS. Racial differences in depression risk should be acknowledged clinically and further explored.
Authors: M Asunción; R M Calvo; J L San Millán; J Sancho; S Avila; H F Escobar-Morreale Journal: J Clin Endocrinol Metab Date: 2000-07 Impact factor: 5.958
Authors: E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: Mary A Whooley; Catarina I Kiefe; Margaret A Chesney; Jerome H Markovitz; Karen Matthews; Stephen B Hulley Journal: Arch Intern Med Date: 2002 Dec 9-23
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Salla Karjula; Laure Morin-Papunen; Stephen Franks; Juha Auvinen; Marjo-Riitta Järvelin; Juha S Tapanainen; Jari Jokelainen; Jouko Miettunen; Terhi T Piltonen Journal: J Clin Endocrinol Metab Date: 2020-06-01 Impact factor: 5.958
Authors: Jessie Benson; Cameron Severn; Julia Hudnut-Beumler; Stacey L Simon; Natalie Abramson; Lauren B Shomaker; Lauren D Gulley; Anya Taylor; Megan M Kelsey; Kristen J Nadeau; Philip S Zeitler; Laura Pyle; Melanie Cree-Green Journal: Can J Diabetes Date: 2020-06-06 Impact factor: 4.190